ZA966083B - Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one. - Google Patents

Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.

Info

Publication number
ZA966083B
ZA966083B ZA9606083A ZA966083A ZA966083B ZA 966083 B ZA966083 B ZA 966083B ZA 9606083 A ZA9606083 A ZA 9606083A ZA 966083 A ZA966083 A ZA 966083A ZA 966083 B ZA966083 B ZA 966083B
Authority
ZA
South Africa
Prior art keywords
dinor
pregn
methylene
hydroxy
ethyl
Prior art date
Application number
ZA9606083A
Inventor
Ralph Lipp
Christian L J Ewers
Clemens Guenther
Jutta Riedl
Ulrich Taeuber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA966083B publication Critical patent/ZA966083B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA9606083A 1995-07-17 1996-07-17 Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one. ZA966083B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19526789 1995-07-17

Publications (1)

Publication Number Publication Date
ZA966083B true ZA966083B (en) 1998-06-19

Family

ID=7767510

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606083A ZA966083B (en) 1995-07-17 1996-07-17 Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.

Country Status (2)

Country Link
DE (1) DE19613698A1 (en)
ZA (1) ZA966083B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323454B2 (en) 2002-05-30 2008-01-29 N.V. Organon Etonogestrel esters

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019171A1 (en) * 2000-04-07 2001-10-18 Schering Ag Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients
DE10211832A1 (en) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormone-containing transdermal therapeutic system with a drug reservoir based on vinyl acetate-vinylpyrrolidone copolymer with improved cohesion

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323454B2 (en) 2002-05-30 2008-01-29 N.V. Organon Etonogestrel esters

Also Published As

Publication number Publication date
DE19613698A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
ZA962536B (en) Pharmaceutical composition for transdermal administration.
AU4809596A (en) Nanosuspensions for intravenous administration
HU9603495D0 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, as pharmaceutical agents
ZA9610729B (en) Transdermal device for the delivery of flurbiprofen.
ZA965190B (en) Pharmaceutical composition.
AU5397996A (en) Iontophoretic transdermal system for the administration of at least two substances
ZA965866B (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
ZA964337B (en) Pharmaceutical compositions containing irbesartan.
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
AU693802B2 (en) Agent for transdermal application containing gestoden esters
ZA967546B (en) Pharmaceutical formulation.
AU7590096A (en) Drug composition
AU6611396A (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
AU5108196A (en) Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
EP0581587A3 (en) Base for transdermal administration.
ZA968081B (en) Pharmaceutical composition.
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
HUT75029A (en) Systems for controlled release of pilocarpine, and semipermeable capsule containing the active ingredient
ZA96796B (en) Transdermal formulation.
ZA966842B (en) Transdermal administration of vorozole.
ZA962752B (en) Rate-controlled transdermal administration of risperidone.
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.